Early Market Access and Pricing with Pete Bak, Christian Thieniel and Brendan Wang

This is the first episode in our podcast series of Q&As on biopharma and medtech development—directly from active developers. Our podcast listeners, including Back Bay clients, have submitted timely and relevant questions about life science development and the daily challenges they face.Christian Thieniel and Brendan Wang, two senior members of the Back Bay Life Science Advisors team with a tremendous amount of experience in the life sciences, especially as it relates to scientific, clinical and commercial issues, offer guidance on issues related to pricing and early market access.Topics include:For early-stage clients, when is the right time to think about pricing and access, and why it is important to identify market access hurdles earlyFor later stage clients, how to get more granular on pricing and market access insights (narrowing the price range, broadening the payer sample, etc.)Which real-life and project examples lend clarity here, including an example from Back Bay’s past work in the anti-infectives space. How can upfront P&MA research lead to more confidence and varied project positioning in partnering discussions?Would you like us to include your life sciences development question in an upcoming episode? Please submit it here.Make sure to subscribe to our podcast on your favorite podcast platforms and follow Back Bay Life Science Advisors on LinkedIn.Thank you for joining us.